Acting as a selective orally-bioavailable inhibitor, Alogliptin readily inhibit the enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, it is processed as a benzoate salt and available predominantly as R-enantiomer. The inhibition of DPP-4 further degrades incretins glucose-dependent insulinotropic polypeptide. Thus, increasing the amount of active plasma incretins, it helps in glycemic control. Moreover, GIP and GLP-1 stimulate the secretion of glucose dependent insulin in pancreatic beta cells.
6-Chloro-3-Methyluracil is an active derivative of Alogliptin and involves the reaction of urea derivative along with malonic acid or its derivative. Widely used in the treatment of diabetic patients, this medicine controls the secretion of glucose.